ReNeuron Group plc Share Purchases by Directors (6843W)
19 April 2019 - 12:40AM
UK Regulatory
TIDMRENE
RNS Number : 6843W
ReNeuron Group plc
18 April 2019
18 April 2019 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchases by Directors
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, was informed on 18 April
2019 that, on the same day, the following purchases of the
Company's ordinary shares of 1p each ("Ordinary Shares") were made
by a director of the Company:
Name Title Number Total beneficial Percentage
of Ordinary interest in of Company's
Shares the Company's Total Voting
purchased Ordinary Shares Rights
Professor
Sir Chris Non-executive
Evans OBE Director 10,000 254,605 0.802
--------------- ------------- ----------------- --------------
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa. ReNeuron is also
advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
detail:
Notification and public disclosure of transactions by persons
discharging managerial
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Professor Sir Chris Evans OBE
-------------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------- ---------------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------- ---------------------------------------
b) Nature of the transaction Purchase of ordinary shares
-------------------------------- ---------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
2.287 10,000
----------
-------------------------------- ---------------------------------------
d) Aggregated information N/A
-------------------------------- ---------------------------------------
e) Date of the transaction 18 April 2019
-------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange AIM Market
-------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGGUBWCUPBGCR
(END) Dow Jones Newswires
April 18, 2019 10:40 ET (14:40 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024